Gilead Sciences upgraded by Maxim Group with a new price target
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Maxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2026 | $127.00 | Outperform → Market Perform | Leerink Partners |
| 7/6/2026 | $155.00 | Hold → Buy | HSBC Securities |
| 5/20/2026 | $165.00 | Hold → Buy | Maxim Group |
| 3/10/2026 | $180.00 | Buy | Jefferies |
| 2/20/2026 | $155.00 | Equal Weight | Barclays |
| 2/11/2026 | $140.00 → $170.00 | Buy | Needham |
| 1/7/2026 | $145.00 | Buy | UBS |
| 11/24/2025 | $140.00 | Buy | Truist |
Submission status for GILEAD SCIENCES INC's drug HEPCLUDEX (ORIG-1) with active ingredient BULEVIRTIDE-GMOD) has changed to 'Approval' on 05/22/2026. Application Category: BLA, Application Number: 761468, Application Classification:
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Labeling
– Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – – Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast Cancer with More than 75,000 Patients Treated Globally – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent fo
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.
–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on ASCENT-03 Study in Which Trodelvy Demonstrated Highly Statistically Significant and Clinically Meaningful Progression-Free Survival (PFS) Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC
4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
Leerink Partners downgraded Gilead Sciences from Outperform to Market Perform and set a new price target of $127.00
HSBC Securities upgraded Gilead Sciences from Hold to Buy and set a new price target of $155.00
Maxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027. "This filing reflects Gilead's continued commitment to advancing new HIV prevention options," said Dietmar Berger, Chief Medical Officer, Gilead Sciences. "Nea
Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the first quarter 2026. "Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Building on the strongest pipeline in Gilead's history, we are adding potentially best-in-disease assets and platforms in oncolog
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D